EUCTR2004-003870-27-GR进行中（未招募）1 期
A prospective, collaborative, international, multicentre, randomised, parallel-group, single and outcome blinded, controlled, factorial trial to investigate the safety and efficacy of treatment with transdermal glyceryl trinitrate, a nitric oxide donor, and of continuing or stopping temporarily pre-stroke antihypertensive therapy, in patients with acute stroke - ENOS
niversity of Nottingham, ResearchHead of research grants and contractsInnovation Services0 个研究点目标入组 4,011 人开始时间: 2012年9月20日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 4,011
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •a) Adult (age > 18 years).
- •b) Clinical stroke syndrome with limb weakness lasting at least 1 hour (i.e. not likely to be a
- •transient ischaemic attack).
- •c) Residual limb weakness at the time of enrolment (SSS Arm <6 and/or Leg <6, appendix C).
- •d) Onset < 48 hours. If the time of onset is unknown, apply the time when the patient was last
- •known to be well. [This timeframe covers the period of maximum uncertainty over altering
- •blood pressure and should permit the vast majority of otherwise eligible patients to be
- •e) Conscious (Glasgow Coma Scale > 8).
- •f) Systolic blood pressure in range 140 mmHg to 220 mmHg inclusive on the basis of at least
- •one of the three baseline pre-randomisation measures.
- •g) Independent prior to stroke (pre-morbid modified Rankin Scale < 2).
- •h) Meaningful consent, or assent from a relative or carer if the patient is unable to give
- •meaningful consent (e.g. in cases of dysphasia, confusion, or reduced conscious level).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •a) Definite need for nitrate therapy: e.g. concurrent myocardial infarction, unstable angina, left
- •ventricular failure. Patients admitted on nitrates for the management of stable angina may
- •stop these for the 7 day trial treatment period.
- •b) Contraindication to nitrate therapy: e.g. hypersensitivity to nitrates, dehydration,
- •hypovolaemia, hypertrophic obstructive cardiomyopathy, aortic stenosis, cardiac
- •tamponade, constrictive pericarditis, mitral stenosis, marked anaemia, closed-angle
- •glaucoma, sildenafil (Viagra) or related drug, within 24 hours.
- •c) Definite need for pre-stroke antihypertensive, anti-anginal or anti-heart failure medication:
- •e.g. concurrent angina, heart failure.
- •d) Definite need for new antihypertensive, anti-anginal or anti-heart failure medication during
- •acute stroke: e.g. concurrent angina, heart failure, hypertensive encephalopathy, aortic
- •dissection.
- •e) Patients expected, on the basis of existing investigations, to require surgical intervention
- •(e.g. clot evacuation, carotid endarterectomy) during the treatment or follow-up period.f) Known intracerebral pathology other than stroke, e.g. subarachnoid haemorrhage, brain
- •tumour, cerebral abscess.
- •g) Other serious condition which is likely to prevent outcome assessment at 90 days, e.g.
- •advanced cancer.
- •h) Previous enrolment in ENOS.
- •i) Current involvement in another trial of an experimental drug. [Patients may be randomised
- •into observational studies or non-drug trials.]
- •j) Not available for follow-up, e.g. no fixed address, overseas visitor.
- •k) Females of childbearing potential where pregnancy cannot be excluded by a negative
- •pregnancy test, pregnancy, or breastfeeding.
- •l) Need for new antihypertensive therapy to lower systolic blood pressure to achieve the
- •enrolment range of 140-220mmHg
- •m) New (not prescribed pre-stroke) antihypertensive medication commenced after stroke onset
研究者
相似试验
进行中（未招募）
1 期
A prospective, collaborative, international, multicentre, randomised, parallel-group, single and outcome blinded, controlled, factorial trial to investigate the safety and efficacy of treatment with transdermal glyceryl trinitrate, a nitric oxide donor, and of continuing or stopping temporarily pre-stroke antihypertensive therapy, in patients with acute strokeAcute strokeMedDRA version: 14.1Level: LLTClassification code 10042244Term: StrokeSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 14.1Level: PTClassification code 10014498Term: Embolic strokeSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 14.1Level: LLTClassification code 10057613Term: Thromboembolic strokeSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 14.1Level: PTClassification code 10061256Term: Ischaemic strokeSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 14.1Level: LLTClassification code 10055221Term: Ischemic strokeSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 14.1Level: LLTClassification code 10067816Term: Cardioembolic strokeSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 14.1Level: LLTClassification code 10027580Term: Middle cerebral artery strokeSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 14.1Level: LLTClassification code 10023027Term: Ischaemic stroke NOSSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 14.1Level: PTClassification code 10043647Term: Thrombotic strokeSystem Organ Class: 10029205 - Nervous system disordersEUCTR2004-003870-27-DKniversity of Nottingham, Research Innovation Services5,000
已完成
不适用
Efficacy of nitric oxide in strokeAcute strokeCirculatory SystemStroke, not specified as haemorrhage or infarctionISRCTN99414122niversity of Nottingham (UK)3,500
进行中（未招募）
1 期
A prospective, international, multi-centre, open-label, phase II study investigating the utility of [68Ga]Ga-PentixaFor PET imaging in response assessment (evaluation of the tumour response to the applied therapy) of primary (primary tumour in brain) and isolated secondary (secondary tumour in brain after relapse of a primary tumour not located in the brain) CNS lymphoma patientsCentral nervous system (CNS) lymphomaMedDRA version: 21.1Level: PTClassification code 10028997Term: Neoplasm malignantSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2021-001711-85-NLPentixaPharm GmbH50
撤回
2 期
A prospective, international, multi-centre, open-label,single-arm phase II study investigating the predictive value of [68Ga]Ga-PentixaFor PET imaging in primary and isolated secondary CNS lymphoma patientsCentral Nervous system lymphomaBrain lymphoma10025322Brain tumorNL-OMON51764PentixaPharm GmbH6
进行中（未招募）
1 期
A prospective, international, multi-centre, open-label, phase II study investigating the utility of [68Ga]Ga-PentixaFor PET imaging in response assessment (evaluation of the tumour response to the applied therapy) of primary (primary tumour in brain) and isolated secondary (secondary tumour in brain after relapse of a primary tumour not located in the brain) CNS lymphoma patientsCentral nervous system (CNS) lymphomaMedDRA version: 21.1Level: PTClassification code 10028997Term: Neoplasm malignantSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2021-001711-85-DKPentixaPharm GmbH50